Funded Biotechnology Startups in Vancouver
The 32 rounds shown span May 2020 through June 2025, with disclosed deal sizes ranging from $30K (Tait Labs, October 2023) to $175M (Alpha9 Theranostics, S…
The 32 rounds shown span May 2020 through June 2025, with disclosed deal sizes ranging from $30K (Tait Labs, October 2023) to $175M (Alpha9 Theranostics, Series C, October 2024). Ten of those rounds closed in 2025 alone, including Aspect Biosystems' $115M Series B in January and four separate deals in May 2025. Most entries carry a "Series Unknown" classification, though named stages include Series A, B, C, and D, alongside post-IPO structures for Sierra Oncology, ESSA Pharma, Mydecine Innovations Group, and BioHarvest Sciences — signaling a cohort that mixes early-stage raises with publicly traded companies still accessing private capital.
Therapeutically, the companies span oncology (Sierra Oncology, enGene, Alpha9 Theranostics), neurology (Alpha Cognition, Lungpacer Medical), antimicrobial biomedical applications (Ondine Biomedical, SaNOtize), plant-derived science (BioHarvest Sciences, Trait Biosciences, Burcon Nutrascience), and antibody discovery (AbCellera Biologics). Nearly all are domiciled in Vancouver, British Columbia, with Geno10X Biosciences representing the single exception as a Vancouver, Alberta entry.
Most recent rounds
32 shownRelated listings
Frequently asked
What are the largest rounds in this dataset?
Alpha9 Theranostics leads with a $175M Series C closed October 23, 2024, followed by Sierra Oncology's $125M Post-IPO Debt round in January 2022, Virogin Biotech's $120M Series D in September 2021, Aspect Biosystems' $115M Series B in January 2025, and AbCellera Biologics' $105M round in May 2020.
How active has Vancouver biotech funding been in 2025?
Ten of the 32 rounds closed in 2025 (through June 11), spanning January through June. Aspect Biosystems anchored the year with a $115M Series B in January, followed by Burcon Nutrascience ($7M, February), two March rounds including Tersa Earth and Geno10X Biosciences, Sirona Biochem in April, four deals in May — Zucara Therapeutics ($5M Series B), BioHarvest Sciences ($4M), Rakovina Therapeutics ($2M), and ME Therapeutics ($100K) — and PreveCeutical Medical ($550K) in June.
What named round stages appear in the data, beyond Series Unknown?
Named stages include Series A (Borealis Biosciences, $30M, December 2024), Series B (Aspect Biosystems $115M, SaNOtize $24M, Zucara Therapeutics $5M), Series C (Alpha9 Theranostics $175M), and Series D (Virogin Biotech $120M). Post-IPO structures appear for Sierra Oncology ($125M debt), ESSA Pharma ($14M equity), Mydecine Innovations Group ($250K equity), and BioHarvest Sciences ($7M debt). Qu Biologics raised $7M via a government grant in October 2022.
Are all companies in the dataset based in Vancouver, BC?
31 of the 32 entries are listed under Vancouver, British Columbia. Geno10X Biosciences — which raised an undisclosed round in March 2025 — is the single outlier, listed under Vancouver, Alberta.
Which company appears more than once in the 32 rows shown?
BioHarvest Sciences appears twice: a $4M round in May 2025 and a $7M Post-IPO Debt round in October 2022. No other company in the dataset has more than one entry.
What is the smallest disclosed round in this dataset?
Tait Labs raised $30K in October 2023, the smallest disclosed amount across all 32 rows. Other sub-$500K rounds include ME Therapeutics ($100K, May 2025), Lancaster Resources ($150K, January 2024), Renaissance BioScience ($170K, February 2024), and Tersa Earth ($240K, March 2025).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.